▶ ORAL GLP-1 RECEPTOR MIMETIC · SUBTOPIC · MECHANISM
ORAL GLP-1 RECEPTOR MIMETIC Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
the originator pharma sponsor oral non-peptide small-molecule GLP-1 receptor agonist (LY3502970). First oral GLP-1 designed for once-daily tablet dosing, bypassing the injection requirement of peptide GLP-1s. ACHIEVE-1 Phase 3 readout expected 2026.
PHARMACOKINETIC HALF-LIFE
Reported half-life for ORAL GLP-1 RECEPTOR MIMETIC: ~24-30 hours (once-daily oral). Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Wharton 2023 NEJM · placebo-subtracted weight loss ~14.7% at 45 mg/day in 36-week Phase 2.
Frias 2023 NEJM · HbA1c reduction up to ~2.1%.
MECHANISM Q+A
▶ What is the oral GLP-1 receptor mimetic?
the oral GLP-1 receptor mimetic (LY3502970) is an orally bioavailable non-peptide small-molecule allosteric agonist of the GLP-1 receptor developed by the originator pharma sponsor. It is the first oral GLP-1 candidate that does not require the specialized absorption formulation used by oral the long-acting GLP-1 agonist.
▶ How is the oral GLP-1 receptor mimetic different from the long-acting GLP-1 agonist?
the oral GLP-1 receptor mimetic is a small molecule taken orally without dietary restriction. the long-acting GLP-1 agonist is a peptide that requires subcutaneous injection or a specialized oral formulation taken on an empty stomach with limited water and at least 30 minutes before eating.
▶ Is the oral GLP-1 receptor mimetic FDA-approved?
Not yet as of 2026-05. Phase 3 ACHIEVE-1 (T2D) and ATTAIN-1 (obesity) programs are ongoing.
▶ How does it work?
the oral GLP-1 receptor mimetic is a positive allosteric modulator of the GLP-1 receptor. It binds outside the orthosteric peptide-binding pocket and stabilizes the active receptor conformation, producing functional agonist activity.
CITED LITERATURE
- Wharton S, et al.. Daily Oral GLP-1 Receptor Agonist the oral GLP-1 receptor mimetic for Adults with Obesity. N Engl J Med 2023. PMID 37364188. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19